Please assess the completion status of the following clinical trial:

Trial Title: A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent obtained prior to study entry?~2. Patient has histologically/cytologically proven, non-resectable or metastatic, adenocarcinoma of the pancreas?~3. Progressive disease during adjuvant chemotherapy (or within 6 month after) or progressive disease during or after first line chemotherapy?~4. Former treatment with chemotherapeutic agent containing gemcitabine?~5. Is the age of the patient ≥ 18 years?~6. Is the ECOG performance status 0-1?~7. Is the absolute neutrophil count (ANC) ≥ 1.5 x 109/l?~8. Is the platelet count ≥ 75 x 109/l?~9. Is the total bilirubin ≤1.5 x UNL (upper normal limit)?~10. Patient has normal liver function? (If liver metastases are present, there is no upper limit for ALAT/SPGT/alk phosph)?~11. Creatinine clearance ≥ 30 ml/min~12. Is the patient capable of following the treatment and the plan of evaluation?~Exclusion Criteria:~1. CTC Grade 3 hyperlipidaemia (\>10.34 mmol/l) in spite of treatment~2. Active former or concurrent history of malignant neoplasm, in the last 2 years?~3. Any condition or therapy which, by the investigators opinion, will expose the patient to a risk or will affect the purpose of the clinical trial?~4. Pregnant or breast feeding patient (fertile patients must use contraceptives)?~5. Infections or other serious medical conditions, which can obstruct the patient's possibility of receiving the treatment? (for instance serious heart, metabolic or lung disease)~6. Known hypersensitivity toward one or more of the parts in the treatment?

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase II: Arm A (Type: EXPERIMENTAL): Regime A-ICE On progression or unacceptable toxicity patients can cross-over from regime A to regime B
- Arm B (Type: ACTIVE_COMPARATOR): Arm B: CapOx On progression or unacceptable toxicity patients can cross-over from regime B to regime A.

Based on this trial design, predict the completion outcome and termination type (if applicable).